Study: AstraZeneca Carries Rare Blood Clot Risk

A new study showed that the AstraZeneca COVID-19 vaccine has a small rare blood clot risk for people, who have low platelets, especially after the first dose and this possibility decreased after the second dose, Reuters reported on Wednesday.

Published in the Lancet medical journal, the study found that the rate of "thrombosis" that accompanied "thrombocytopenia" syndrome after the first dose of the vaccine was 8.1 per million.

However, this rate decreased to 2.3 per million after receiving the second shot of the AstraZeneca vaccine.

The vaccine set several controversial situations between European Union members amid discovering rare blood clotting in vaccinated adults which drove various countries to suspend or restrict using the vaccine.

However, the European Medicine Agency (EMA) asserted that it is safe, regardless of the rare percentage of causing blood clots.